Author

N. Nicot

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Bikfalvi· 1 shared A. Bousard· 1 shared A. Burban· 1 shared A. Sharanek· 1 shared B. Dartigues· 1 shared B. Klink· 1 shared C. Bosc· 1 shared C. Joffre· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bikfalvi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Exploiting a metabolic vulnerability in brain tumour stem cells using a brain-penetrant drug with safe profile

A. Burban, C. Tessier, M. Pinglaut, J. Guyon, J. Galvis, B. Dartigues, M. Toujas, M. Larroquette, H. A. Luchman, S. Weiss, N. Nicot, B. Klink, M. Nikolski, L. Brisson, T. Mathivet, , A. Sharanek

This study shows that mubritinib targets brain tumour stem cells by inhibiting complex I of the electron transport chain, delays glioblastoma tumourigenesis, and is safe in mice.

bioRxiv · Jan 15, 2024Cancer Biology

Mitochondrial determinants of response and resistance to venetoclax plus cytarabine duplet therapy in acute myeloid leukemia

C. Bosc, N. Gadaud, A. Bousard, M. Sabatier, G. Cognet, E. Saland, T. Farge, E. Boet, M. Gotanegre, N. Aroua, P.-L. Mouchel, C. Larrue, L. Jarrou, F. Rambow, F. Cabon, , J.-E. Sarry

This study identifies mitochondrial determinants of response and resistance to venetoclax plus cytarabine therapy in AML, showing that OxPHOS is a predictive marker and that targeting ETCI improves outcomes.

bioRxiv · Aug 17, 2020 · PreprintCancer Biology